GSK-249553/004

Study Sponsor: GSK

Study Title

A Phase IIB Study to Assess the Efficacy of GSK 249553 as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection

Medicine or Vaccine (generic name)

SB249553

Sponsor Identification Number

249553/004

Trial Registry Identification Number(#'s)

NCT00290355

Medical Condition

Lung Cancer, Non-Small Cell

Phase

Phase 2

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=249553/004

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00290355

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

September 2017